N-(3-(5-chloroindolin-1-yl)-3-oxopropyl)-3,5-bis(trifluoromethyl)benzamide | 1207113-97-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(3-(5-chloroindolin-1-yl)-3-oxopropyl)-3,5-bis(trifluoromethyl)benzamide
• 英文别名: N-[3-(5-chloro-2,3-dihydroindol-1-yl)-3-oxopropyl]-3,5-bis(trifluoromethyl)benzamide
• CAS: 1207113-97-0
• 化学式: C₂₀H₁₅ClF₆N₂O₂
• 分子量: 464.795
• InChiKey: JWKTWVWHUNZTCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  5-氯吲哚啉 、 [[3,5-bis(trifluoromethyl)benzoyl]amino]propanoic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 N-(3-(5-chloroindolin-1-yl)-3-oxopropyl)-3,5-bis(trifluoromethyl)benzamide
  参考文献：
  名称：

  Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423

  摘要：

  We recently identified bis(amide) CCG-1423 (1) as a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis. An initial structure-activity relationship study focusing on bioisosteric replacement of the amides and conformational restriction identified two compounds, 4g and 8, with improved selectivity for inhibition of RhoA/C-mediated gene transcription and attenuated cytotoxicity relative to 1. Both compounds were also capable of inhibiting cell invasion with equal efficacy to 1 but with less attendant cytotoxicity. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.056

文献信息

• METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION
  申请人：Neubig Richard

  公开号：US20120252792A1

  公开（公告）日：2012-10-04

  The invention provides methods, compositions, and kits for the inhibition of members of the Rho GTPase family. Specifically, the invention provides methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signalling. The invention finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis, inflammation, inflammatory disease), Rho-mediated biological conditions, and in cell signaling research.

  本发明提供了抑制Rho GTPase家族成员的方法、组合物和试剂盒。具体来说，本发明提供了抑制RhoA和/或RhoC转录信号的方法、组合物和试剂盒。本发明可用于治疗Rho介导的疾病状态（例如肿瘤转移、炎症、炎症性疾病）、Rho介导的生物条件以及细胞信号研究。
• [EN] METHODS AND COMPOSITIONS FOR INHIBITING RHO-MEDIATED DISEASES AND CONDITIONS<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR INHIBER DES MALADIES ET DES ÉTATS À MÉDIATION PAR RHO
  申请人：UNIV MICHIGAN

  公开号：WO2011035143A2

  公开（公告）日：2011-03-24

  The invention provides methods, compositions, and kits for the inhibition of members of the Rho GTPase family. Specifically, the invention provides methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signalling. The invention finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis, inflammation, inflammatory disease), Rho-mediated biological conditions, and in cell signaling research.
• Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423
  作者：Chris R. Evelyn、Jessica L. Bell、Jenny G. Ryu、Susan M. Wade、Andrew Kocab、Nicole L. Harzdorf、H.D. Hollis Showalter、Richard R. Neubig、Scott D. Larsen

  DOI：10.1016/j.bmcl.2009.11.056

  日期：2010.1

  We recently identified bis(amide) CCG-1423 (1) as a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis. An initial structure-activity relationship study focusing on bioisosteric replacement of the amides and conformational restriction identified two compounds, 4g and 8, with improved selectivity for inhibition of RhoA/C-mediated gene transcription and attenuated cytotoxicity relative to 1. Both compounds were also capable of inhibiting cell invasion with equal efficacy to 1 but with less attendant cytotoxicity. (C) 2009 Elsevier Ltd. All rights reserved.